Key result
Recent studies suggest that NT-proBNP may be used as a biochemical marker to differentiate cardioembolic strokes from non-cardioembolic strokes.
Why the study?
Can NT-proBNP be used as a biomarker to differentiate cardioembolic stroke from non-cardioembolic stroke?
NT-proBNP is highlighted as a potential biomarker to identify cardioembolic stroke, which could help guide appropriate anticoagulation therapy.
May inform early stroke etiology assessment; leaves open integration into algorithms pending prospective validation.
Cardioembolic stroke generally results in more severe disability, since it typically has a larger ischemic area than the other types of ischemic stroke. The correct identification of a stroke etiology as cardioembolic is important as it has been shown that these patients benefit from anticoagulation. However, it is difficult to differentiate cardioembolic strokes from non-cardioembolic strokes (atherothrombotic stroke and lacunar stroke). NT-proBNP is a well recognized biochemical marker of congestive heart failure. Recent studies suggest that NT-proBNP may be used as a marker of cardioembolic stroke.
No takes yet. Share an insight, caveat, or question.
Renjen et al. (2013) conducted a review in Acute Cardioembolic Stroke. Plasma N-Terminal ProB-Type Natriuretic Peptide (NT-ProBNP) Level was evaluated. Recent studies suggest that NT-proBNP may be used as a biochemical marker to differentiate cardioembolic strokes from non-cardioembolic strokes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: